2012 Major League Baseball Drug Suspensions
2012 Major League Baseball Drug Suspensions
Filed under: drug treatment programs in san francisco
Page 1 of 1. Players who have been suspended this season for violating the Major League Baseball Joint Drug Prevention and Treatment Program (x-second offense): x-RHP Guillermo Mota, San Francisco, May 7, 100 games (clenbuterol). INF Freddy Galvis …
Read more on San Francisco Chronicle
Bayer Submits New Drug Application for Regorafenib for the Treatment of …
Filed under: drug treatment programs in san francisco
WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., Aug. 30, 2012 — /PRNewswire/ — Bayer HealthCare and Onyx Pharmaceuticals (NASDAQ: ONXX) today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food …
Read more on The Herald | HeraldOnline.com
Targeting Gilead, AIDS Healthcare Foundation seeks SF referendum on HIV …
Filed under: drug treatment programs in san francisco
The AIDS Healthcare Foundation wants a San Francisco referendum to push city officials to negotiate prescription drug prices. The proposed … Since 2008, Gilead has had a voluntary price freeze for state AIDS Drug Assistance Programs. That has been …
Read more on San Francisco Business Times (blog)
PRO BASEBALL: A's Colon suspended for positive test
Filed under: drug treatment programs in san francisco
Five players have been suspended this year under the big league drug program. San Francisco reliever Guillermo Mota was penalized 100 games in May following his second positive test and is eligible to return Aug. 28. Philadelphia infielder Freddy …
Read more on San Angelo Standard Times
What’s the significance of the FDA’s approval of Truvada to prevent HIV transmission? – In what some experts are calling a “game-changing” endorsement by the US Food and Drug Administration (FDA), the commonly used HIV drug Truvada is now approved for preventing HIV. The drug was already approved for treating people infected with HIV, and it is also already prescribed “off-label” for preventing HIV. But the FDA endorsement opens up the possibility for more widespread use, since it gives insurance companies a new labeled indication for using the drug. In this video, UCSF’s Brad Hare talks about the significance of this approval. C. Bradley Hare, MD is an Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF) and Medical Director of the UCSF Positive Health Program at San Francisco General Hospital and Trauma Center (SFGH)